Vaxcyte, Inc. — Director's Dealing 2022

Jun 23, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-06-21

Reporting Person: PICKERING GRANT (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-21	Common Stock	S	5451	$21.0487	Disposed	700005	Direct
2022-06-22	Common Stock	S	1261	$21.0089	Disposed	698744	Direct
2022-06-23	Common Stock	S	3541	$21.0139	Disposed	695203	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	355660	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.31. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.065. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $21.00 to $21.09. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.